1CM
VRNA

1492 Capital Management’s Verona Pharma VRNA Stock Holding History

1492 Capital Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-98,057
Closed -$9.27M – 125
2025
Q2 		$9.27M Sell
98,057
-1,270
-1% -$94K 4.27% 1
2025
Q1 		$6.31M Sell
99,327
-675
-0.7% -$40.4K 3.39% 2
2024
Q4 		$4.64M Sell
100,002
-61,053
-38% -$2.29M 2.21% 15
2024
Q3 		$4.63M Sell
161,055
-2,592
-2% -$63.8K 2.31% 14
2024
Q2 		$2.37M Sell
163,647
-616
-0.4% -$8.99K 1.34% 34
2024
Q1 		$2.64M Sell
164,263
-1,775
-1% -$30.7K 1.47% 29
2023
Q4 		$3.3M Buy
166,038
+1,579
+1% +$23.3K 1.88% 18
2023
Q3 		$2.68M Buy
164,459
+23,261
+16% +$448K 1.73% 18
2023
Q2 		$2.98M Buy
141,198
+75,359
+114% +$1.61M 1.74% 19
2023
Q1 		$1.32M Sell
65,839
-23
-0% -$497 0.82% 46
2022
Q4 		$1.72M Hold
65,862
– – 1.11% 31
2022
Q3 		$673K Buy
+65,862
New +$555K 0.48% 69

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

1492 Capital Management's VRNA Position: Q3 2025 in Review

1492 Capital Management sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 98,057 shares — an estimated $9.27M sold.

1492 Capital Management first reported a position in VRNA in Q3 2022 and held it in 12 quarters. The position peaked at $9.27M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • 1492 Capital Management reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • 1492 Capital Management sold 98,057 Verona Pharma shares in Q3 2025, an estimated $9.27M.
  • 1492 Capital Management first reported a position in Verona Pharma in Q3 2022 and held it in 12 quarters.
  • 1492 Capital Management's Verona Pharma position peaked at $9.27M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on 1492 Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.